Agilent Technologies Inc vs Procter & Gamble Co — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Procter & Gamble Co trades at $146.14 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 8.1× Agilent Technologies Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| A | PG | |
|---|---|---|
Market Cap | $42.00B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $167.18 |
52-Week Low | $110.24 | $138.10 |
Enterprise Value | $43.55B | $366.23B |
Dividend Yield | 0.69% | 2.97% |
Volume | — | 6,423,436 |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Procter & Gamble (PG) trades at $145.21, down 0.38% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.43 beating expectations of $1.41. Revenue reached $84.28 billion in 2025 with net income of $15.97 billion, supported by a robust 18.44% net margin and 30.13% ROE. Recent developments include a new WNBA partnership and a $1.09 dividend declaration for August 2026 payment.
PG offers stable dividend income with 69 consecutive years of increases, but faces premium valuation concerns at 22.12 P/E ratio. Analyst consensus targets $161.20 with 53% buy ratings, suggesting 11% upside potential. Key risks include soft demand outlook and elevated valuation multiples compared to peers. The stock presents a defensive investment opportunity amid market volatility, though near-term growth appears modest.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →